{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=26", "query": { "intervention": "Phase 1b", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 2481, "total_pages": 249, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=27&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=25&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T15:36:37.096Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04669067", "title": "TL-895 and KRT-232 Study in Acute Myeloid Leukemia", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "TL-895", "type": "DRUG" }, { "name": "KRT-232", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Telios Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2021-03-31", "completion_date": "2025-11", "has_results": false, "last_update_posted_date": "2023-02-17", "last_synced_at": "2026-10-20T15:36:37.096Z", "location_count": 11, "location_summary": "Los Angeles, California • Orange, California • Augusta, Georgia + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04669067" }, { "nct_id": "NCT01933672", "title": "Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "PF-04937319 once-daily", "type": "DRUG" }, { "name": "PF-04937319 split-dose", "type": "DRUG" }, { "name": "Sitagliptin once-daily", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 33, "start_date": "2013-10", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2016-09-27", "last_synced_at": "2026-10-20T15:36:37.096Z", "location_count": 8, "location_summary": "DeLand, Florida • South Miami, Florida • High Point, North Carolina + 3 more", "locations": [ { "city": "DeLand", "state": "Florida" }, { "city": "South Miami", "state": "Florida" }, { "city": "South Miami", "state": "Florida" }, { "city": "High Point", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01933672" }, { "nct_id": "NCT04660812", "title": "An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "AB680", "type": "DRUG" }, { "name": "Etrumadenant", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "m-FOLFOX-6 regimen", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 227, "start_date": "2021-05-10", "completion_date": "2025-09-05", "has_results": false, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-10-20T15:36:37.096Z", "location_count": 17, "location_summary": "Tucson, Arizona • Duarte, California • Santa Monica, California + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04660812" }, { "nct_id": "NCT03960645", "title": "Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "FEMALE", "summary": "18 Years to 39 Years · Female only" }, "enrollment_count": 62, "start_date": "2019-06-28", "completion_date": "2022-08-18", "has_results": true, "last_update_posted_date": "2024-06-14", "last_synced_at": "2026-10-20T15:36:37.096Z", "location_count": 2, "location_summary": "Ft. Pierce, Florida • West Palm Beach, Florida", "locations": [ { "city": "Ft. Pierce", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03960645" }, { "nct_id": "NCT06789172", "title": "A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumours", "Sarcoma", "HNSCC", "Non Small Cell Lung Cancer", "NSCLC", "Colorectal Cancer (CRC)", "Myxofibrosarcoma (MFS)", "Solitary Fibrous Tumors", "Dedifferentiated Liposarcoma", "Undifferentiated Pleomorphic Sarcoma (UPS)", "Leiomyosarcoma", "Leiomyosarcoma (LMS)", "Gastric Cancer (GC)", "Gastric Cancer Adenocarcinoma Metastatic", "Gastric / Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "OKN4395", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Fasting", "type": "OTHER" }, { "name": "Fed", "type": "OTHER" }, { "name": "H2 Receptor Antagonist", "type": "DRUG" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT", "OTHER" ], "sponsor": "Epkin", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 146, "start_date": "2025-01-23", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-20T15:36:37.096Z", "location_count": 3, "location_summary": "Beverly Hills, California • Santa Monica, California • Houston, Texas", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06789172" }, { "nct_id": "NCT04104139", "title": "TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rectal Adenocarcinoma", "Stage IIA Rectal Cancer AJCC v8", "Stage IIB Rectal Cancer AJCC v8", "Stage III Rectal Cancer AJCC v8", "Stage IIIA Rectal Cancer AJCC v8", "Stage IIIB Rectal Cancer AJCC v8", "Stage IIIC Rectal Cancer AJCC v8" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2019-12-11", "completion_date": "2025-07-15", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-20T15:36:37.096Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04104139" }, { "nct_id": "NCT04806035", "title": "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CLL", "SLL", "Richter's Transformation", "Indolent Lymphoma", "Follicular Lymphoma", "Marginal Zone Lymphoma", "Aggressive Lymphoma", "DLBCL", "Mediastinal Large B-cell Lymphoma", "MCL" ], "interventions": [ { "name": "TG-1801", "type": "BIOLOGICAL" }, { "name": "Ublituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2021-04-28", "completion_date": "2024-06-12", "has_results": false, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-20T15:36:37.096Z", "location_count": 5, "location_summary": "Fayetteville, Arkansas • Hackensack, New Jersey • Chattanooga, Tennessee + 2 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Chattanooga", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04806035" }, { "nct_id": "NCT03658135", "title": "BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Tauopathies", "Corticobasal Degeneration Syndrome", "Frontotemporal Lobar Degeneration With Tau Inclusions", "MAPT Mutation Carriers, Symptomatic", "Traumatic Encephalopathy Syndrome", "Nonfluent Aphasia, Progressive" ], "interventions": [ { "name": "BIIB092", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "35 Years to 80 Years" }, "enrollment_count": 22, "start_date": "2018-09-12", "completion_date": "2019-12-13", "has_results": false, "last_update_posted_date": "2019-12-19", "last_synced_at": "2026-10-20T15:36:37.096Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03658135" }, { "nct_id": "NCT05386108", "title": "Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Neoplasms", "Brain Neoplasms", "Neoplasms by Site", "Neoplasms", "Breast Diseases", "Central Nervous System Neoplasms", "Brain Diseases", "Central Nervous System Diseases" ], "interventions": [ { "name": "Elacestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stemline Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2022-08-31", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-20T15:36:37.096Z", "location_count": 11, "location_summary": "Fullerton, California • Los Angeles, California • Urbana, Illinois + 8 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05386108" }, { "nct_id": "NCT00840333", "title": "\"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients\"", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "MP-376 (Levofloxacin solution for Inhalation)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "6 Years to 16 Years" }, "enrollment_count": 27, "start_date": "2009-04", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2024-12-04", "last_synced_at": "2026-10-20T15:36:37.096Z", "location_count": 6, "location_summary": "Mobile, Alabama • San Diego, California • Orlando, Florida + 3 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00840333" } ] }